TY - JOUR
T1 - Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users
T2 - The Study to Reduce Intravenous Exposures (STRIVE)
AU - Kapadia, Farzana
AU - Latka, Mary H.
AU - Hagan, Holly
AU - Golub, Elizabeth T.
AU - Campbell, Jennifer V.
AU - Coady, Micaela H.
AU - Garfein, Richard S.
AU - Thomas, David L.
AU - Bonner, Sebastian
AU - Thiel, Thelma
AU - Strathdee, Steffanie A.
N1 - Funding Information:
Funding for this project was provided by the National Institute on Drug Abuse through grant DA14499. Trial registration: Study to Reduce Intravenous Exposures, NCT00391482, http://clinicaltrials.gov/ct/show/NCT00391482?order=1.
PY - 2007/1
Y1 - 2007/1
N2 - Hepatitis C virus (HCV) is hyperendemic among injection drug users (IDUs). However, few scientifically proven interventions to prevent secondary transmission of HCV from infected IDUs to others exist. This report describes the design, feasibility, and baseline characteristics of participants enrolled in the Study to Reduce Intravenous Exposure (STRIVE). STRIVE was a multisite, randomized-control trial to test a behavioral intervention developed to reduce distribution of used injection equipment (needles, cookers, cottons, and rinse water) and increase health-care utilization among antibody HCV (anti-HCV) positive IDUs. STRIVE enrolled anti-HCV positive IDU in Baltimore, New York City, and Seattle; participants completed behavioral assessments and venipuncture for HIV, HCV-RNA, and liver function tests (LFTs) and were randomized to attend either a six-session, small-group, peer-mentoring intervention workshop or a time-matched, attention-control condition. Follow-up visits were conducted at 3 and 6 months. At baseline, of the 630 HCV-positive IDUs enrolled (mean age of 26 years, 60% white, 76% male), 55% reported distributive needle sharing, whereas 74, 69, and 69% reported sharing cookers, cottons, and rinse water, respectively. Health-care access was low, with 41% reporting an emergency room as their main source of medical care. Among those enrolled, 66% (418/630) were randomized: 53% (222/418) and 47% (196/418) to the intervention and control conditions, respectively. Follow-up rates were 70 and 73% for the 3- and 6-month visits, respectively. As distributive sharing of used injection equipment was common while reports of receiving HCV care were low, these findings indicate an urgent need for HCV-related interventions with IDUs and demonstrate the acceptability and feasibility to do so.
AB - Hepatitis C virus (HCV) is hyperendemic among injection drug users (IDUs). However, few scientifically proven interventions to prevent secondary transmission of HCV from infected IDUs to others exist. This report describes the design, feasibility, and baseline characteristics of participants enrolled in the Study to Reduce Intravenous Exposure (STRIVE). STRIVE was a multisite, randomized-control trial to test a behavioral intervention developed to reduce distribution of used injection equipment (needles, cookers, cottons, and rinse water) and increase health-care utilization among antibody HCV (anti-HCV) positive IDUs. STRIVE enrolled anti-HCV positive IDU in Baltimore, New York City, and Seattle; participants completed behavioral assessments and venipuncture for HIV, HCV-RNA, and liver function tests (LFTs) and were randomized to attend either a six-session, small-group, peer-mentoring intervention workshop or a time-matched, attention-control condition. Follow-up visits were conducted at 3 and 6 months. At baseline, of the 630 HCV-positive IDUs enrolled (mean age of 26 years, 60% white, 76% male), 55% reported distributive needle sharing, whereas 74, 69, and 69% reported sharing cookers, cottons, and rinse water, respectively. Health-care access was low, with 41% reporting an emergency room as their main source of medical care. Among those enrolled, 66% (418/630) were randomized: 53% (222/418) and 47% (196/418) to the intervention and control conditions, respectively. Follow-up rates were 70 and 73% for the 3- and 6-month visits, respectively. As distributive sharing of used injection equipment was common while reports of receiving HCV care were low, these findings indicate an urgent need for HCV-related interventions with IDUs and demonstrate the acceptability and feasibility to do so.
KW - Behavioral intervention
KW - Health-care utilization
KW - Hepatitis C virus
KW - Injection drug user
KW - Randomized trial
UR - http://www.scopus.com/inward/record.url?scp=33846413986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846413986&partnerID=8YFLogxK
U2 - 10.1007/s11524-006-9133-7
DO - 10.1007/s11524-006-9133-7
M3 - Article
C2 - 17200799
AN - SCOPUS:33846413986
SN - 1099-3460
VL - 84
SP - 99
EP - 115
JO - Journal of Urban Health
JF - Journal of Urban Health
IS - 1
ER -